uCloudlink Group, Inc. engages in the provision of data connectivity services. The firm is also involved in selling Wi-Fi terminals and data related products to enable personal and enterprise users to access mobile internet. The company was founded by Chao Hui Chen and Zhi Ping Peng on August 25, 2014 and is headquartered in Hong Kong.
相关临床试验
0
0 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
暂无试验阶段数据
暂无试验数据
暂无试验数据
暂无批准数据
- Researchers at UCL developed CAR T cells that precisely kill cancer cells carrying the CALR mutation without harming other blood cells. - The therapy was validated using patient samples, a lab model recreating human bone marrow, and studies in mice. - A Phase I clinical trial is planned at UCLH, aiming to begin within one to two years pending funding and regulatory approval. - The approach targets myeloproliferative neoplasms (MPNs), chronic blood cancers that can progress to myelofibrosis with bone marrow scarring and anaemia.
- A large UK trial found antihistamines and colchicine provided a small additional reduction in long Covid fatigue at 12 weeks (1.5 points on a 40-point scale), but the benefit was not sustained at 24 weeks after stopping treatment. - The blood thinner rivaroxaban showed no benefit for long Covid fatigue, and the researchers concluded results do not support anticoagulation for this condition. - All trial groups, including those receiving only specialist long Covid care, experienced meaningful fatigue improvement (4.3 points), underscoring the value of integrated multidisciplinary clinic care. - The STIMULATE-ICP trial, involving nearly 800 adults across 12 UK clinics, is considered a gold-standard benchmark study in the international long Covid research field.
- A groundbreaking base-edited CAR-T cell therapy called BE-CAR7 achieved 82% deep remission rates in patients with previously untreatable T-cell acute lymphoblastic leukemia. - Clinical trial results published in the New England Journal of Medicine show 64% of patients remain disease-free, with some now three years post-treatment. - The therapy uses advanced base-editing technology to create "universal" donor T-cells that can target and destroy leukemic T-cells without requiring patient matching. - Great Ormond Street Hospital Charity has committed over £2 million to support treatment for an additional 10 patients in an extended trial cohort.
- Researchers at UCL and University of Oxford will begin the world's first clinical trial of LungVax, an experimental vaccine designed to prevent lung cancer by training the immune system to recognize and destroy early abnormal lung cells. - The phase I trial, funded with up to £2.06 million from Cancer Research UK, will start in summer 2026 and focus on high-risk individuals including early-stage lung cancer survivors and participants in NHS screening programs. - LungVax uses genetic instructions to help immune cells identify "red flag" proteins called neoantigens and tumor-associated antigens that appear on the surface of cells in the earliest stages of lung cancer formation. - The vaccine represents a shift toward cancer prevention rather than treatment, though researchers emphasize it would complement rather than replace smoking cessation as the primary method of reducing lung cancer risk.
- The Decipher Prostate Genomic Classifier test successfully identified metastatic prostate cancer patients who benefit from docetaxel chemotherapy, showing a 36% reduction in death risk for high-scoring patients. - Among 832 metastatic prostate cancer patients in the STAMPEDE trial, those with high Decipher scores had significant survival improvement with docetaxel, while lower-scoring patients showed minimal benefit. - The 22-gene test becomes the first molecular diagnostic with randomized trial evidence to guide chemotherapy decisions in metastatic prostate cancer, potentially sparing patients from unnecessary treatment side effects. - Additional analysis revealed that combining Decipher scores with PTEN status further refined patient selection, with high Decipher/PTEN inactive tumors showing 45% reduction in death hazards with docetaxel.
- Researchers at University College London and Great Ormond Street Hospital have successfully developed and delivered the world's first gene therapy for P47 chronic granulomatous disease, treating a 19-year-old patient named Remi in June 2024. - The treatment uses the patient's own stem cells modified with a functional copy of the NCF1 gene via lentiviral vector, eliminating rejection risks associated with traditional bone marrow transplants. - Within weeks of treatment, the patient began producing healthy immune cells capable of fighting infections, representing a significant milestone in personalized medicine for rare genetic disorders. - The therapy was developed, manufactured, and delivered entirely under one roof at the Zayed Centre for Research into Rare Disease in Children, potentially accelerating future gene therapy development timelines.
- Cambridge Healthcare Innovations has announced Quattrii, a dry powder inhaler engine capable of delivering large volumes of biologic and mRNA molecules in a single inhalation with at least 70% lung delivery efficiency. - The technology separates active drugs from lactose carriers during delivery, reducing inert powder inhalation and potentially enabling novel therapies for lung cancer, Parkinson's disease, and pain management. - Quattrii will be available for pharmaceutical companies to use in Phase 1 clinical trials starting Q4 2025, representing a significant advancement over existing inhalers that typically deliver only 10-50% of drugs to the lungs.
- A new smartphone-based digital motor score (HDDMS) developed by UCL and Roche researchers demonstrates twice the sensitivity of current clinical measures in detecting Huntington's disease progression. - The five-minute home-based assessment could reduce clinical trial participant requirements and study durations, potentially accelerating drug development for this devastating neurodegenerative condition. - Research involving 1,048 participants across four studies shows the digital biomarker approach offers convenient, reliable monitoring of motor symptoms outside clinical settings.
- Yaqrit has received a £2.2 million ($2.85 million) grant from the UK's National Institute for Health and Care Research to fund pivotal trials of its DIALIVE liver support device across 13 UK centers. - The DIALIVE device treats Acute-on-Chronic Liver Failure (ACLF) by removing disease-causing toxins from blood and exchanging dysfunctional albumin, showing twice the resolution rate compared to standard care in previous studies. - The randomized trial will enroll approximately 70 high-risk ACLF grade 2-3 patients, with results expected in Q1 2027, potentially offering new hope for a condition that carries 40-80% mortality within 28 days.
- The UK maintains world-leading position in life sciences research and innovation, but faces significant challenges in translating scientific discoveries into domestic manufacturing capabilities. - Manufacturing's contribution to UK GDP has halved over two decades, while competing nations in Europe and US are increasing their production investments and capabilities. - High visa costs up to 17 times higher than competitor nations and concentration of resources in the Golden Triangle region are hindering UK's ability to attract global talent and develop nationwide life sciences infrastructure.
